Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0596 CAR-T Cell Injection in Relapsed/Refractory Multiple Myeloma
NCT07760454Phase 2Recruiting
- Sponsor
- CARsgen Therapeutics
- Start
- Sep 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CT0596 in multiple myeloma (MM), sponsored by CARsgen Therapeutics. Primary endpoints: Adverse Events at 24 months, Maximum Tolerated Dose and/or Recommended Phase II Dose at 28 days and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
CT0596
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07760454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07760454.